Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on September 22, 2017, reporting events that occurred on September 18, 2017. The filing addresses corporate governance changes specifically regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and does not contain financial performance data.
Material Changes
The Board of Directors filled two vacancies with the following appointments:
- Cristina Csimma, Pharm.D, MHP: Appointed as a Class III director.
- Zhuo Zhang: Appointed as a Class III director and designated as the director for the Series A 4.5% Convertible Preferred Stock, appointed by the sole holder, Tianjin Pharmaceuticals Group International Holdings Co., LTD.
Following these appointments, the Board consists of 7 acting directors. Both new directors will serve until the 2020 annual shareholders meeting or until resignation/removal.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on operations, risks, contingencies, or unusual items. Compensation for the new directors will follow the Company's non-executive board compensation plan described in a prior Form 8-K filed on June 27, 2017.
Investor Verification Checklist
- Verify the total number of board seats and the specific term expiration dates for Class III directors.
- Review the June 27, 2017 Form 8-K to understand the specific compensation structure for non-executive directors.
- Confirm the voting rights and influence of the Series A 4.5% Convertible Preferred Stock holder regarding Mr. Zhang's appointment.
- Check for any subsequent filings regarding the resignation or removal of the newly appointed directors.